2012年至2024年关于基于Pyrazole的抗癌剂与SAR研究的研究的综述
Deepali Wanode1, Deweshri Nandurkar2, Megha Ambatkar1
1Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, India.
Current topics in medicinal chemistry
|June 13, 2025
概括
皮拉衍生物作为抗癌剂显著有前途. 本综述涵盖了2012年至2024年的研究,重点是FDA批准和临床试验的基于皮拉的化疗药物.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 皮拉衍生物因其抗癌性质而越来越多地受到研究.
- 新型化疗剂的开发对于癌症治疗至关重要.
- 现有的基于皮拉的药物和临床试验中的药物表明了治疗潜力.
研究的目的:
- 提供对pyrazole衍生物作为抗癌剂的综合性审查.
- 分析2012年至2024年这一领域的研究趋势.
- 以指导未来的研究和开发基于pyrazole的癌症疗法.
主要方法:
- 科学出版物和临床试验数据的文献综述.
- 分析合成皮拉衍生物与报告的抗癌活性.
- 专注于食品和药物管理局 (FDA) 批准的化合物和临床试验中的化合物.
主要成果:
- 识别了许多具有显著抗癌活性的pyrazole衍生物.
- 美国食品和药物管理局批准的基于皮拉的化疗药物的文档.
- 目前正在进行癌症治疗临床试验的皮拉衍生物的概述.
结论:
- 皮拉衍生物在癌症研究中代表了一类重要的化合物.
- 对于开发下一代癌症疗法而言,对皮拉衍生物的持续研究至关重要.
- 这一审查作为未来创新基于pyrazole的瘤学的基础.
相关概念视频
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis
407
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
407
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
279
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
279


